
via University of Reading
An antioxidant drug reverses atherosclerosis and could be used to prevent heart attacks and strokes due to clots, according to research funded by the British Heart Foundation (BHF) and published today in JAHA: Journal of the American Heart Association.
Atherosclerosis is the build-up of fatty deposits in the arteries. When a type of fat called LDL cholesterol becomes oxidised and builds up to form plaques in the artery walls, inflammation and damage increase which can cause the plaques to rupture and cause blood to clot.
These clots can block vital arteries that allow blood to flow to the heart, causing a heart attack, or to the brain causing a stroke.
Previously, researchers at the University of Reading discovered that LDL cholesterol can be oxidised in acidic small ‘bags’ called lysosomes in immune cells within the artery wall.
Now, Professor David Leake and his team have found that the antioxidant drug, cysteamine, has the power to switch off, and even reverse, this damaging process.
Cysteamine works by accumulating in the lysosomes and stops the oxidation of LDL cholesterol. It is already known to be safe in humans where it’s used to treat a rare lysosomal disease called cystinosis.
When the researchers looked at mice with atherosclerosis, those treated with cysteamine had a 32 to 56 per cent reduction in the size of atherosclerotic plaques depending on the part of the aorta – the largest artery in the body – that was examined.
Cysteamine decreased the amount of oxidised fat by 73 per cent and increased the stability of the atherosclerotic areas. It decreased the proportion of inflammatory white blood cells by 55 per cent and increased the area made up of smooth muscle cells by 85 per cent, ultimately reducing the chance of plaques rupturing and causing a blood clot.
Antioxidant drugs that have previously produced promising results in mice have proven disappointing in clinical trials to treat cardiovascular disease, but the researchers hope that with these promising results, cysteamine will prove a successful treatment in humans.
Professor David Leake, Professor of Biomedical Sciences at the University of Reading who led the study said:
“The potential in this drug to protect against heart attacks and strokes and ultimately save lives superseded our expectations. We hoped it would cause plaques to grow at a slower pace, but we were amazed to find it reversed the process.
“Cysteamine would offer an entirely new way of treating atherosclerosis. We now want to look at the most efficient way to give this drug to patients, and hope that it can be taken to clinical trials in the next few years.”
Professor James Leiper, Associate Medical Director at the British Heart Foundation, which funded the research said:
“Heart attacks and strokes threaten the lives of people too often. In the UK, every 5 minutes someone is admitted to hospital with a heart attack, and the same is true of stroke. “The more ways we can find to treat the root cause of cardiovascular disease, the more lives and livelihoods that can be saved.
“If this antioxidant drug can show the same promising effects in humans, then it could offer a lifeline to thousands of people in the future.”
Original Article: ANTIOXIDANT DRUG REVERSES PROCESS RESPONSIBLE FOR HEART ATTACKS AND STROKES
More from: University of Reading
The Latest Updates from Bing News & Google News
Go deeper with Bing News on:
Cysteamine
- Struggling Poultry Farmers Seek Support To Avoid Bankruptcyon May 21, 2023 at 10:11 am
HÀ NỘI - Việt Nam Poultry Association (VIPA) has submitted a petition to Government calling for solutions to remov ...
- Rampant low-cost chicken import threatens domestic farmerson May 18, 2023 at 9:17 pm
Tens of thousands of tonnes of low-priced chicken are imported into Vietnam illegally every month, challenging domestic chicken farmers.
- Analyst Says Gene Therapy Data Update Offers Insights into Potential Pivotal Endpointson May 18, 2023 at 11:32 am
Avrobio Inc (NASDAQ: AVRO) shares are trading higher after the company announced follow-up data demonstrating a durable treatment effect across key measures out to 36 months from a Phase 1/2 trial of ...
- Got Pigmentation? Derms Can’t Stop Raving About Cysteamine, the Safe Counterpart to Hydroquinoneon February 19, 2023 at 11:04 am
For that you need something like cysteamine, an ingredient praised for its ability to decrease melanin pigment and fade dark spots on the skin when applied topically. It can even help prevent ...
- Late Effects of Gamma Radiation on Mice protected with Cysteamine or Cystamineon December 20, 2022 at 8:34 am
D. J. MEWISSEN and MARSHALL BRUCER: under contract with the United States Atomic Energy Commission. D. J. MEWISSEN: Work done while a resident physician at the Medical Division, Oak Ridge ...
Go deeper with Google Headlines on:
Cysteamine
[google_news title=”” keyword=”cysteamine” num_posts=”5″ blurb_length=”0″ show_thumb=”left”]
Go deeper with Bing News on:
Treating atherosclerosis
- Vascular Proliferation and Atherosclerosis: New Perspectives and Therapeutic Strategieson May 26, 2023 at 5:00 pm
Atherosclerosis involves multiple processes ... Thus, an emerging strategy for the treatment of those conditions is to inhibit cellular proliferation by targeting cell cycle regulation.
- Showing patients their plaque pics pushes them to address heart riskson May 26, 2023 at 12:44 am
Researchers have found that showing patients images of the plaque buildup in their arteries not only educates them but also provides motivation to address the risk factors associated with ...
- Why atherosclerosis puts older women at greater riskon May 25, 2023 at 9:49 pm
What is atherosclerosis and why does it put postmenopausal women at a greater risk of having a heart attack than men and younger women? More ...
- Patients With SLE Have 4-Fold Higher Risk for Atherosclerotic Plaque Progressionon May 23, 2023 at 9:12 am
Compared with the general population, patients with SLE are at a 3-fold greater risk for subclinical atherosclerosis. In 2022, the European Alliance of Associations for Rheumatology (EULAR) guidelines ...
- High LDL, Poor Treatment, Early Death: HoFH Registry Paints Grim Pictureon May 23, 2023 at 7:16 am
Among those who died with this rare genetic lipid disorder, half did so before they reached their third decade.
Go deeper with Google Headlines on:
Treating atherosclerosis
[google_news title=”” keyword=”treating atherosclerosis” num_posts=”5″ blurb_length=”0″ show_thumb=”left”]